Savara Inc. develops therapies for rare respiratory diseases, with a lead program in molgramostim inhalation solution, conditionally named MOLBREEVI, for autoimmune pulmonary alveolar proteinosis. Molgramostim is a recombinant human GM-CSF delivered through an investigational eFlow Nebulizer System developed for inhalation of the large-molecule therapy.
Recurring company developments include clinical data from the IMPALA-2 program, regulatory submissions and agency-review updates in the U.S., Europe and the U.K., financial results, financing arrangements, equity inducement grants and investor conference participation. Savara's updates also note that MOLBREEVI is not approved in any indication.
Savara Inc. (Nasdaq: SVRA) has announced its participation in upcoming virtual fireside chats at key investor healthcare conferences. The Piper Sandler Annual Healthcare Conference will feature a recorded chat available until December 3, 2020, with a replay on Savara's website. Additionally, the Evercore ISI Annual HealthCONx Conference is scheduled for December 3, 2020, at 12:35 PM EST, with a live webcast accessible online. Both events will have replays for 90 days. Savara focuses on orphan lung diseases, with three investigational inhaled compounds in development.
Savara Inc. (Nasdaq: SVRA), a company focused on orphan lung diseases, announced that Chairman and Interim CEO Matthew Pauls will present at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 2:55 PM EST. Interested parties can access a live audio webcast via Savara's Investors page. The company’s pipeline includes three inhaled investigational compounds: Molgradex for autoimmune pulmonary alveolar proteinosis, AeroVanc for MRSA lung infections in cystic fibrosis, and Apulmiq for non-CF bronchiectasis.